开能健康(300272.SZ)：子公司拟收购原能集团部分子公司股权

Core Viewpoint - The company, Kaineng Health, has signed an equity acquisition agreement to purchase 100% stakes in several subsidiaries of the Yuanneng Group, which will enhance its control over the cell industry chain and create business synergies [1][2] Group 1: Acquisition Details - Kaineng Health's wholly-owned subsidiary, Hainan Kaineng Cell, will acquire 100% equity of Yuanneng Lishui's Yuan Tian Biotechnology and Lishui Dongxin, as well as 100% equity of Kele Cat and Jiyuan Meiyu held by the Yuanneng Group for a cash consideration of 203.82 million yuan [2] - The acquisition will not have a significant impact on the company's financial status and operating results for the current year [1] Group 2: Business Synergies - The acquired companies are all part of the same control group under the Yuanneng Group, ensuring that the relationship remains consistent post-acquisition [1] - There are existing business synergies among the acquired companies, such as Yuan Tian Biotechnology providing research and raw material support for Jiyuan Meiyu's cell factor cosmetics, and technical support for pet health anti-aging business to Laisen Yuan [1]